The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.
 
Virginie Westeel
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
 
Guillaume Eberst
Honoraria - Bristol-Myers Squibb
 
Amelie Anota
Honoraria - Roche
Travel, Accommodations, Expenses - Hospira; Novartis; Pfizer
 
Arnaud Scherpereel
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Jacques Margery
No Relationships to Disclose
 
Laurent Greillier
No Relationships to Disclose
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sysmex
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Msd (Inst); Novartis (Inst); Pfizer (Inst); Roche; Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Denis Moro-Sibilot
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Pfizer; Roche
 
Olivier Molinier
No Relationships to Disclose
 
Lena Herve
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Lilly; Roche/Genentech
 
Frédéric Rivière
No Relationships to Disclose
 
Isabelle Monnet
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Pfizer
 
Valérie Gounant
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer; Roche
 
Henri Janicot
No Relationships to Disclose
 
Radj Gervais
No Relationships to Disclose
 
Chrystele Locher
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); ROCHE (Inst); Roche (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche